5-HT 3 antagonists: A new class of anxiolytic drugs? The example of ondansetron;Antagonistas 5-HT 3: Uma nova classe de ansioliticos? O exemplo do ondansetron

Revista de Psiquiatria Clinica

Volumn 27, Issue 5, 2000, Pages 272-279

  Tonelli, Denise Gianoti ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

5 HT 3 antagonists; Anxiety; Non systematic review; Ondansetron; Serotonin

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ANXIETY NEUROSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; REVIEW;

EID: 0033660441     PISSN: 01016083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Efeito amnesico dos benzodiazepinicos
2. 3 receptor antagonist with anxiolytic-like properties in animal models
3. Characterization of serotoninergic mechanism involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice
4. 3 receptors mediate inhibition of acetylcholine release in cortical tissue
5. Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety
6. Release of endogenous dopamine by stimulation of 5-hydroxitryptamine3 receptors in rat striatum
7. Serotoninergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices
8. Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task
9. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment
10. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological response in young healthy controls
11. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset
12. 3 receptor antagonist
13. 3) receptor antagonists increase rates of punished responding in rats
14. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens
15. Actions of 5-hydroxytryptophan to inhibit and desinhibit mouse behaviour in the light/dark test
16. Inhibition of [H-3] gamma-amino-butyric-acid release from guinea-pig hippocampal synaptosomes by serotonergic agents
17. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse
18. 3 receptor agonist and antagonist for alteration of aversive behaviour in the mouse
19. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine.2.the social interactions
20. 5-HT and mechanisms of defense
21. 3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans
22. 3 receptors and GABAergic neurons inhibiting acetylcholine release in rat ethorhinal cortex slices
23. 3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat
24. Efficacy of ondansetron in the treatment of generalized anxiety disorder
25. Serotonergic modulation of acetylcholine release from cortex of freely moving rats
26. Behavioral studies with anxiolytic drugs. V.I. Effects on punished responding of drugs interacting with serotonin receptor subtypes
27. Impairment of perfomance associated with long-term use of benzodiazepines
28. Biological and behavioral responses to d-amphetamine alone and in combination with the serotonin(3) receptor antagonist ondansetron in healthy volunteers
29. Ansiedade
30. 3 receptor antagonists: Clinical pharmacology and therapeutics applications
31. Risk assessment behaviour: Evaluation of utility in the study of 5-HT - Related drug in the rat elevated plus-maze test
32. A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects
33. 3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal
34. 3 receptors control dopamine release in the nucleus acumbbens of freely moving rats
35. 3-receptor antagonist
36. 3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine
37. A randomized double-blind placebo-controlled study of topisetron in the treatment of outpatients with generalized anxiety disorder
38. Serotoninergic modulation of anticholinergic effects on cognition and behavior in elderly humans
39. Neuropeptides and anxiety: Focus on cholecystokinin
40. 3 receptors in the control of 5-HT release in the rat hippocampus in vivo
41. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood-flow
42. 3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia
43. Effects of various serotoninergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference
44. Ondansetron: Therapeutic use as an antiemetic
45. Potentiation of physical dependence on diazepam by ondansetron in rats
46. Effects of serotoninergic anxiolytics on physical dependence on diazepam in mice
47. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs
48. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening antipanic drugs
49. 3 receptor antagonists, GR 38032F and BRL 24924, on anxiety in socially isolated rats
50. 3 receptor can reduce the fear-potentiated startle response in the rat: Evidence for diferent types of anxiolytic activity
51. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents
52. An anxiolytic-like effect of ondansetron disapears in oxazepam-tolerant rats
53. Ultrasonic vocalizations in rat pups: Effcetcs of serotonergic ligands
54. 3 receptor antagonists and anxiety: A preclinical and clinical review
55. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats
56. Different effects of topisetron and ondansetron in learning and memory paradigms
57. Benzodiazepinicos e desempenho psicomotor e cognitivo
58. 3 receptor antagonists of release of cholecystokinin-like immunoreactivity from frontal cortex of freely moving rats
59. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs
60. A pharmacological analysis of the mode of action of serotonin (5-HT) upon the guinea-pig ileum
61. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety in mice
62. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine: 2. The elevated plus-maze
63. 3 antagonist, in benzodiazepine discontinuation
64. 3 antagonist
65. Effects of ondansetron on short - Term memory retrieval in mice
66. 3 antagonist, in a novel animal model
67. Serotoninergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box
68. 5-HT(1A) receptors play an important role in modulation of behavior of rats in a two-compartment black and white box
69. Ondansetron in the treatment of panic disorder
70. Ondansetron and opiate craving. A novel pharmacological approach to addiction
71. 3 antagonist ondansetron in alcohol abuse and dependence
72. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxitriptamine-3 antagonist, in the treatment of anxiety
73. 3 receptor antagonism and psychoactivity
74. Social phobia: A review of pharmacologic treatment
75. 3 receptor-independence inhibition of the depolarization induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron
76. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: III. Clinical features affecting experts' therapeutic recommendations in anxiety disorders
77. Ondansetron modulates GABA(A) current of rat central nervous system neurons
78. Consequences of 1989 New York triplicate benzodiazepine prescription regulations
79. Ondansetron: A review of its pharmacology and preliminary clinical findings in novel applications
80. Stress-induced hyperthermia as a putative anxiety model